SABCS 2023: Treatment Post CDK 4/6 Inhibitors
Dr. Stephanie L. Graff, MD moderates this session on breast cancer treatment options after progression on CDK 4/6 inhibtors. 1. Single agent endocrine therapy with Carlos H. Barrios, MD 2. Combination endocrine therapy following progression on first-line therapy with Ruth O'Regan, MD 3. When to transition to cytotoxics with Erica Stringer-Reasor, MD 4. Treatment Decisions: A Patient's Perspective with Abigail M. Johnston, JD
▶︎
Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors
▶︎
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
▶︎
SABCS 2023: Trends in Adjuvant Endocrine Therapy
▶︎
JCO PO Article Insights: Longitudinal Monitoring of Anti-EGFR Based Therapy in CRC
▶︎
Brian Greene and Leonard Susskind: Quantum Mechanics, Black Holes and String Theory
▶︎
LRR Pediatrics for FMGE 2026 By Dr. Meenakshi Bothra
▶︎
Mechanistic Activity and Development History of CDK 4/6 Inhibitors
▶︎
"La guerra di Trump? Nelle nostre tasche: tra riarmo e finanza siamo il bancomat di Wall Street"
▶︎
AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD
▶︎
LRR Microbiology for FMGE 2026 By Dr. Preeti Sharma
▶︎
Rymanowski, Miller: UPA-dek przyjaźni?
▶︎
Indistinguishable from Magic: When Fantasy and Science Fiction Meet the Science of Medicine
▶︎
RL for Agents Workshop - Deep Dive on Training Agents with RL and Open Source
▶︎
Historian Timothy Snyder on ENDING Trump Nightmare FOR GOOD | PoliticsGirl
▶︎
Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika Hamilton
▶︎
DIRECTO | Powell se somete al Congreso: ¿dará más pistas de la bajada de tipos?
▶︎
Understanding Your Myeloma Labs: What They Mean, What Matters, and When to Ask Questions
▶︎
Breast Cancer Treatment: How CDK4/6 Inhibitors Work (monarchE & NATALEE Trials)
▶︎
Breast Cancer Treatment Plan- Kisqali - Letrozole Cycle 1- How did it go? Side Effects? Diagnosis?
▶︎